Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • RFK Jr.’s Future
  • Melanoma Drug
  • Charity Care Gap
  • Search for New FDA Chief

WHAT'S NEW

  • RFK Jr.'s Future
  • Melanoma Drug
  • Charity Care Gap
  • Search for New FDA Chief

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Sep 6 2023

Full Issue

Perspectives: ADHD Med Shortage Shows No Sign Of Easing; Why Are Pro-Life Groups Targeting PEPFAR?

Read recent commentaries about pharmaceutical issues.

USA Today: Adderall Shortage Is Still Happening. Don't Expect A Quick Remedy

A 27-year-old patient of mine has taken Adderall since early adolescence. A successful bonds trader who works long hours, he gives Adderall part of the credit for his success in business. (Dr. Marc Siegel, 9/5)

The New York Times: I’m A Pro-Life Priest. Anti-Abortion Groups Are Wrong To Oppose PEPFAR

The debate over PEPFAR kicked off in May when the Heritage Foundation, a conservative think tank, published a report that, without any substantiation, accused PEPFAR of “promoting” abortion. That same report callously referred to H.I.V. as a “lifestyle disease” and framed antiretroviral therapy as a partisan talking point. (Richard W. Bauer, 9/5)

The New York Times: 4 Arguments You Will Hear Against Medicare Drug Price Negotiations

President Biden recently announced the first 10 drugs that will be subject to price negotiations with Medicare. They include drugs to treat diabetes, heart disease, blood cancer, blood clots and rheumatoid arthritis — diseases that affect millions of Americans. (Larry Levitt, 9/6)

Bloomberg: Ozempic Cuts Alcohol Cravings. Liquor, Beer And Wine Companies Aren’t Ready

The alcohol industry has been thriving despite a streak of threats: the legalization of marijuana, a trade war with China that has hampered US exports, the rise of the sober-curious movement. Now a new risk, one few investors or companies are publicly acknowledging, could pressure sales: weight loss drugs. (Lisa Jarvis and Leticia Miranda, 9/1)

The New York Times: A Filmmaker’s Final Goodbye To Opiates 

For most of my adult life, I’ve struggled with an opiate addiction of some form. But I’m one of the lucky ones, because I’m still here. The dark descent into the nefarious underworld of heroin addiction is well documented, but the challenging and deeply personal world of recovery and hope is rarely seen. (Miranda Stern, 9/5)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 15
  • Thursday, May 14
  • Wednesday, May 13
  • Tuesday, May 12
  • Monday, May 11
  • Friday, May 8
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF